Literature DB >> 15485615

Proteomics in cancer screening and management in gynecologic cancer.

Wei Hu1, Weiguo Wu, Ryuji Kobayashi, John J Kavanagh.   

Abstract

Biomarkers are used routinely for population screening, disease diagnosis and prognosis, monitoring of therapy, and prediction of therapeutic response. Unfortunately, most biomarkers have low sensitivity and specificity and little predictive value. Novel techniques for better screening and early diagnosis of ovarian cancer are urgently needed. Proteomics, the study of the cellular proteins and their activation states, integrates some fundamental techniques, including high-throughput protein purification and profiling, genomic and proteomic databases, and mass spectrometry. In oncology, proteomics will contribute greatly to our understanding of gene functions in tumor development and provide information in clinical applications. This article reviews proteomic techniques and their potential applications in gynecologic cancer screening and management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485615     DOI: 10.1007/s11912-004-0076-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  49 in total

1.  The PSIPRED protein structure prediction server.

Authors:  L J McGuffin; K Bryson; D T Jones
Journal:  Bioinformatics       Date:  2000-04       Impact factor: 6.937

Review 2.  The role of separation science in proteomics research.

Authors:  H J Issaq
Journal:  Electrophoresis       Date:  2001-10       Impact factor: 3.535

3.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?

Authors:  Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

Review 4.  Clinical proteomics: translating benchside promise into bedside reality.

Authors:  Emanuel F Petricoin; Kathryn C Zoon; Elise C Kohn; J Carl Barrett; Lance A Liotta
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

5.  High-resolution serum proteomic features for ovarian cancer detection.

Authors:  T P Conrads; V A Fusaro; S Ross; D Johann; V Rajapakse; B A Hitt; S M Steinberg; E C Kohn; D A Fishman; G Whitely; J C Barrett; L A Liotta; E F Petricoin; T D Veenstra
Journal:  Endocr Relat Cancer       Date:  2004-06       Impact factor: 5.678

6.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

Authors:  Eleftherios P Diamandis
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

7.  Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.

Authors:  Monica Brown Jones; Henry Krutzsch; Hungjun Shu; Yingming Zhao; Lance A Liotta; Elise C Kohn; Emmanuel F Petricoin
Journal:  Proteomics       Date:  2002-01       Impact factor: 3.984

Review 8.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

9.  Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry.

Authors:  Travis W Young; Fang C Mei; Gong Yang; Jennifer A Thompson-Lanza; Jinsong Liu; Xiaodong Cheng
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

Review 10.  CA 125: the past and the future.

Authors:  R C Bast; F J Xu; Y H Yu; S Barnhill; Z Zhang; G B Mills
Journal:  Int J Biol Markers       Date:  1998 Oct-Dec       Impact factor: 3.248

View more
  1 in total

1.  Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.

Authors:  Beate Gericke; Jens Raila; Jalid Sehouli; Sophie Haebel; Dominique Könsgen; Alexander Mustea; Florian J Schweigert
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.